HTB

HIV treatment bulletin

RSS 2 RSS Atom Atom • ISSN 1472-4683 • SubscribeAbout

On the web

Medscape conference coverage, based on selected sessions at the 6th International Congress on Drug Therapy in HIV Infection

17-21 November 2002, Glasgow, Scotland

Resistance and response to subsequent treatment following virologic failure of tenofovir-based therapy
Graeme Moyle
http://www.medscape.com/viewarticle/446683

Once-daily fosamprenavir/ritonavir appears comparable to twice-daily nelfinavir
W. David Hardy
http://www.medscape.com/viewarticle/446684

Efficacy of T-20 holds up across subgroups with varying demographics and disease status
W. David Hardy
http://www.medscape.com/viewarticle/446685

Nelfinavir Is less effective but better tolerated than ritonavir in advanced disease
Graeme Moyle
http://www.medscape.com/viewarticle/446686

Zidovudine is metabolized to stavudine triphosphate in human cells
Graeme Moyle
http://www.medscape.com/viewarticle/446687
Levels of abacavir and lamivudine in semen
Mike Youle
http://www.medscape.com/viewarticle/446688

Cellular expression of multidrug transporters only modestly affects intracellular PI levels
Graeme Moyle
http://www.medscape.com/viewarticle/446689

Lactic acid metabolism is affected both by baseline level and by HIV infection itself
W. David Hardy
http://www.medscape.com/viewarticle/446690

Sexual transmission of hepatitis C
Mike Youle
http://www.medscape.com/viewarticle/446691

Links to external websites are current at time of posting but not maintained.

HIV i-Base
Treatment phoneline: 0808 800 6013 • Mon-Wed 12-4pm • Office: 020 7407 8488 • Email: admin@i-base.org.uk • Website: www.i-base.info